Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2014

01-06-2014 | Original Article

Proposal of remission criteria for IgA nephropathy

Authors: Yusuke Suzuki, Keiichi Matsuzaki, Hitoshi Suzuki, Naoko Sakamoto, Kensuke Joh, Tetsuya Kawamura, Yasuhiko Tomino, Seiichi Matsuo

Published in: Clinical and Experimental Nephrology | Issue 3/2014

Login to get access

Abstract

Background

The remission criteria of immunoglobulin A (IgA) nephropathy have varied depending on the clinical study. Therefore, nephrologists cannot make a uniform assessment of treatment outcomes and the standardization of explanations of the condition is difficult in patients with IgA nephropathy. This study aims to propose clinical remission criteria for IgA nephropathy based on a nationwide opinion survey in Japan regarding IgA nephropathy remission/relapse.

Method

This nationwide survey was sent to 312 teaching facilities of the Japanese Society of Nephrology by Progressive Renal Disease Research, Research on Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan.

Results

Valid answers were obtained from 193 facilities (61.9 %) (136 internal medicine facilities and 57 pediatric facilities), of which 134 (69.4 %) thought that both hematuria and proteinuria should be used in the remission standards. Approximately half of the survey respondents shared the opinion on standards of negative results for hematuria and proteinuria and the duration and frequency of these conditions.

Conclusion

In this paper, we propose a standardized set of criteria for defining IgA nephropathy remission: three consecutive negative results over a 6-month period in urinary occult blood tests; urinary sediment red blood cell count of <5/high-power field (hematuria remission); and urinary protein of <0.3 g/day (g/g Cr; proteinuria remission). Clinical remission is defined as cases with both hematuria and proteinuria remission. These consensus-based remission criteria should be verified in future studies. In the meantime, they may be useful in predicting therapeutic outcome in cases of IgA nephropathy.
Literature
1.
go back to reference Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef
2.
go back to reference Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.PubMedCrossRef Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.PubMedCrossRef
3.
go back to reference Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef
5.
go back to reference Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83.PubMedCrossRef Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83.PubMedCrossRef
6.
go back to reference Hwang HS, Kim BS, Shin YS, et al. Predictors for progression in immunoglobulin A nephropathy with significant proteinuria. Nephrology. 2010;15:236–41.PubMedCrossRef Hwang HS, Kim BS, Shin YS, et al. Predictors for progression in immunoglobulin A nephropathy with significant proteinuria. Nephrology. 2010;15:236–41.PubMedCrossRef
7.
go back to reference Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol. 2012;16:883–91.PubMedCrossRef Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol. 2012;16:883–91.PubMedCrossRef
8.
go back to reference Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.PubMedCrossRef Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.PubMedCrossRef
9.
go back to reference Iseki K, Tokashiki K, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.PubMedCrossRef Iseki K, Tokashiki K, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.PubMedCrossRef
10.
go back to reference Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.PubMedCrossRef Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.PubMedCrossRef
11.
go back to reference Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.PubMedCrossRef Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.PubMedCrossRef
12.
go back to reference Endo M. Epidemiology and prognosis of IgA nephropathy. Nihon Jinzo Gakkai Shi. 2008;50:442–7.PubMed Endo M. Epidemiology and prognosis of IgA nephropathy. Nihon Jinzo Gakkai Shi. 2008;50:442–7.PubMed
13.
go back to reference Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transpl. 2009;24:3068–74.CrossRef Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transpl. 2009;24:3068–74.CrossRef
14.
go back to reference Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.PubMedCrossRef Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.PubMedCrossRef
15.
go back to reference Shen P, He L, Li Y, et al. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106(4):c157–61.PubMedCrossRef Shen P, He L, Li Y, et al. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106(4):c157–61.PubMedCrossRef
16.
go back to reference Scientific Committee, Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Tokyo: Tokyo Igakusya; 2009. Scientific Committee, Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Tokyo: Tokyo Igakusya; 2009.
17.
go back to reference Commitee for Diagnostic Guidelines of Hematuria. Guidelines for diagnosis of hematuria. Nihon Jinzo Gakkai Shi. 2006;48(Suppl):1–34. Commitee for Diagnostic Guidelines of Hematuria. Guidelines for diagnosis of hematuria. Nihon Jinzo Gakkai Shi. 2006;48(Suppl):1–34.
18.
go back to reference Committee of revision of clinical practice guidebook 2012 for diagnosis and treatment of CKD. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Tokyo: Tokyo Igakusha; 2012. Committee of revision of clinical practice guidebook 2012 for diagnosis and treatment of CKD. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Tokyo: Tokyo Igakusha; 2012.
19.
go back to reference Japanese Society of Nephrology. Nephrotic syndrome diagnosis guidelines. Nihon Jinzo Gakkai Shi. 2011;53:78–122. Japanese Society of Nephrology. Nephrotic syndrome diagnosis guidelines. Nihon Jinzo Gakkai Shi. 2011;53:78–122.
Metadata
Title
Proposal of remission criteria for IgA nephropathy
Authors
Yusuke Suzuki
Keiichi Matsuzaki
Hitoshi Suzuki
Naoko Sakamoto
Kensuke Joh
Tetsuya Kawamura
Yasuhiko Tomino
Seiichi Matsuo
Publication date
01-06-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0849-x

Other articles of this Issue 3/2014

Clinical and Experimental Nephrology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.